文献速递帕金森病与运动障碍

匹莫范色林用于老年帕金森病患者与住院及死亡风险的相关性

Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
PubMed 文献 · Neurology · 2021-08-13

结果显示,匹莫范色林使用与30天住院风险升高相关(aHR 1.24,95%CI 1.06-1.43),并与90天、180天及1年死亡风险升高相关。

要点

  • 匹莫范色林使用与30天住院风险升高相关(aHR 1.24,95%CI 1.06-1.43)。
  • 匹莫范色林使用与90天死亡风险升高相关(aHR 1.20,95%CI 1.02-1.41)。
  • 死亡风险升高持续至180天(aHR 1.28)和1年(aHR 1.56)。

核心结论

  • 在65岁及以上居住在Medicare认证长期护理机构的帕金森病患者中,匹莫范色林使用与30天住院风险升高及长达1年的死亡风险升高相关。

研究设计与样本

  • 回顾性队列研究,使用Medicare认证长期护理机构居民的管理数据集及关联Medicare索赔数据。
  • 采用倾向评分逆概率治疗加权(IPTW)平衡24项基线特征,使用Fine-Gray竞争风险模型和Cox比例风险回归模型估计风险。

主要发现

  • 匹莫范色林使用与30天住院风险升高相关(IPTW调整后风险比[aHR] 1.24,95%置信区间[CI] 1.06-1.43)。
  • 匹莫范色林使用与90天住院风险无显著关联(aHR 1.10,95%CI 0.99-1.24)。
  • 匹莫范色林使用与30天死亡风险无显著关联(aHR 0.76,95%CI 0.56-1.03)。
  • 匹莫范色林使用与90天死亡风险升高相关(aHR 1.20,95%CI 1.02-1.41),180天(aHR 1.28,95%CI 1.13-1.45)和1年(aHR 1.56,95%CI 1.42-1.72)时仍持续。

临床怎么用

  • 在老年帕金森病患者中处方匹莫范色林时,应权衡其潜在获益与住院及死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To determine the risk of hospitalization and death associated with pimavanserin use. METHODS: We conducted a retrospective cohort study of adults 65 years and older with Parkinson disease between November 1, 2015, and December 31, 2018, using an administrative dataset on residents of Medicare-certified long-term care facilities and linked Medicare claims data. Propensity score-based inverse probability of treatment weighting (IPTW) was used to balance pimavanserin users and nonusers on 24 baseline characteristics. Fine-Gray competing risk and Cox proportional hazards regression models were used to estimate the risk of hospitalization and death up to 1 year, respectively. RESULTS: The study cohort included 2,186 pimavanserin users and 18,212 nonusers. There was a higher risk of 30-day hospitalization with pimavanserin use vs nonuse (IPTW-adjusted hazard ratio [aHR] 1.24, 95% confidence intervals [CI] 1.06-1.43). There was no association of pimavanserin use with 90-day hospitalization (aHR 1.10, CI 0.99-1.24) or with 30-day mortality (aHR 0.76, CI 0.56-1.03). Pimavanserin use vs nonuse was associated with increased 90-day mortality (aHR 1.20, CI 1.02-1.41) that persisted after 180 days (aHR 1.28, CI 1.13-1.45) and 1 year (aHR 1.56, CI 1.42-1.72). DISCUSSION: Pimavanserin use vs nonuse in older adults was associated with an increased risk of hospitalization at 1 month of initiation and a higher risk of death for up to 1 year following initiation. These findings, in a large real-world cohort within long-term care facilities, may help to inform decisions regarding its risk/benefit balance among patients with Parkinson disease. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with Parkinson disease who are 65 or older and residing in Medicare-certified long-term care facilities, pimavanserin is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hwang YJ, Alexander GC, An H, et al. Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology. 2021. PMID: 34389652. doi:10.1212/WNL.0000000000012601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。